Trial Outcomes & Findings for Tracking Post-stroke Walking Improvements From the Clinic Into the Home (NCT NCT05454007)

NCT ID: NCT05454007

Last Updated: 2026-07-24

Results Overview

The normalized difference between short step length and long step length; a spatial parameter absolute value of (left step length - right step length) / left step length + right step length Will be compared across timepoints.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

53 participants

Primary outcome timeframe

In-clinic baseline (day 1), in-home baseline (day 1)

Results posted on

2026-07-24

Participant Flow

Participants were recruited from local hospitals, medical facilities, support groups, and community businesses.

Participant milestones

Participant milestones
Measure
Individuals With Stroke
Individuals with stroke who meet inclusion and exclusion criteria were included in Aim 1 and Aim 2 of the study. In aim 1, they engaged in a standard neurological screen and participated in clinic- and home-based walking trials. In Aim 2, they underwent a single session of step length symmetry training and submitted a series of home walking videos to track how durable improvements were from the clinic to home.
Neurologically Intact Adults
Healthy Adults/Adults without Stroke participated in Aim 1, but not Aim 2 of the study. They underwent the same screening and neurological assessment as participants with stroke and performed clinic-based and home-based walking trials. They did not receive intervention.
Overall Study
STARTED
23
30
Overall Study
COMPLETED
21
29
Overall Study
NOT COMPLETED
2
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Individuals With Stroke
Individuals with stroke who meet inclusion and exclusion criteria were included in Aim 1 and Aim 2 of the study. In aim 1, they engaged in a standard neurological screen and participated in clinic- and home-based walking trials. In Aim 2, they underwent a single session of step length symmetry training and submitted a series of home walking videos to track how durable improvements were from the clinic to home.
Neurologically Intact Adults
Healthy Adults/Adults without Stroke participated in Aim 1, but not Aim 2 of the study. They underwent the same screening and neurological assessment as participants with stroke and performed clinic-based and home-based walking trials. They did not receive intervention.
Overall Study
Withdrawal by Subject
2
1

Baseline Characteristics

Tracking Post-stroke Walking Improvements From the Clinic Into the Home

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Individuals With Stroke
n=18 Participants
Individuals with stroke who meet inclusion and exclusion criteria were included in Aim 1 and Aim 2 of the study. In aim 1, they engaged in a standard neurological screen and participated in clinic- and home-based walking trials. In Aim 2, they underwent a single session of step length symmetry training and submitted a series of home walking videos to track how durable improvements were from the clinic to home.
Neurologically Intact Adults
n=25 Participants
Healthy Adults/Adults without Stroke participated in Aim 1, but not Aim 2 of the study. They underwent the same screening and neurological assessment as participants with stroke and performed clinic-based and home-based walking trials. They did not receive intervention.
Total
n=43 Participants
Total of all reporting groups
Age, Continuous
66.72 years
STANDARD_DEVIATION 14.72 • n=9 Participants
72.40 years
STANDARD_DEVIATION 8.59 • n=27 Participants
70.02 years
STANDARD_DEVIATION 11.74 • n=267 Participants
Sex: Female, Male
Female
7 Participants
n=9 Participants
19 Participants
n=27 Participants
26 Participants
n=267 Participants
Sex: Female, Male
Male
11 Participants
n=9 Participants
6 Participants
n=27 Participants
17 Participants
n=267 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=9 Participants
0 Participants
n=27 Participants
1 Participants
n=267 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
17 Participants
n=9 Participants
25 Participants
n=27 Participants
42 Participants
n=267 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=9 Participants
0 Participants
n=27 Participants
0 Participants
n=267 Participants

PRIMARY outcome

Timeframe: In-clinic baseline (day 1), in-home baseline (day 1)

Population: Data from three individuals with stroke and three individuals without stroke were excluded from analysis due to insufficient data quality. Issues included pixelated or blurry videos, failure to keep the recording device stationary, or inaccurate identification of key landmarks during pose estimation. Ultimately, the data from 43 participants were included in data analysis.

The normalized difference between short step length and long step length; a spatial parameter absolute value of (left step length - right step length) / left step length + right step length Will be compared across timepoints.

Outcome measures

Outcome measures
Measure
Individuals With Stroke
n=18 Participants
Individuals with stroke who meet inclusion and exclusion criteria were included in Aim 1 and Aim 2 of the study. In aim 1, they engaged in a standard neurological screen and participated in clinic- and home-based walking trials. In Aim 2, they underwent a single session of step length symmetry training and submitted a series of home walking videos to track how durable improvements were from the clinic to home.
Neurologically Intact Adults
n=25 Participants
Healthy Adults/Adults without Stroke participated in Aim 1, but not Aim 2 of the study. They underwent the same screening and neurological assessment as participants with stroke and performed clinic-based and home-based walking trials. They did not receive intervention.
Step Length Asymmetry
Clinic Data - Baseline
0.12 unitless
Standard Deviation 0.11
0.07 unitless
Standard Deviation 0.07
Step Length Asymmetry
Home Data - Baseline
0.15 unitless
Standard Deviation 0.11
0.07 unitless
Standard Deviation 0.04

PRIMARY outcome

Timeframe: In-clinic baseline (day 1), in-home baseline (day 1)

Population: Data from three individuals with stroke and three individuals without stroke were excluded from analysis due to insufficient data quality. Issues included pixelated or blurry videos, failure to keep the recording device stationary, or inaccurate identification of key landmarks during pose estimation. Ultimately, the data from 43 participants were included in data analysis.

The normalized difference between short step time and long step time; a temporal parameter (absolute value(left step time- right step time))/(left step time + right step time) Will be compared across timepoints.

Outcome measures

Outcome measures
Measure
Individuals With Stroke
n=18 Participants
Individuals with stroke who meet inclusion and exclusion criteria were included in Aim 1 and Aim 2 of the study. In aim 1, they engaged in a standard neurological screen and participated in clinic- and home-based walking trials. In Aim 2, they underwent a single session of step length symmetry training and submitted a series of home walking videos to track how durable improvements were from the clinic to home.
Neurologically Intact Adults
n=25 Participants
Healthy Adults/Adults without Stroke participated in Aim 1, but not Aim 2 of the study. They underwent the same screening and neurological assessment as participants with stroke and performed clinic-based and home-based walking trials. They did not receive intervention.
Step Time Symmetry
Clinic Data - Baseline
0.10 unitless
Standard Deviation 0.14
0.05 unitless
Standard Deviation 0.07
Step Time Symmetry
Home Data - Baseline
0.11 unitless
Standard Deviation 0.15
0.04 unitless
Standard Deviation 0.02

PRIMARY outcome

Timeframe: In-clinic baseline (day 1), in-home baseline (day 1)

Population: Data from three individuals with stroke and three individuals without stroke were excluded from analysis due to insufficient data quality. Issues included pixelated or blurry videos, failure to keep the recording device stationary, or inaccurate identification of key landmarks during pose estimation. Ultimately, the data from 43 participants were included in data analysis.

The speed at which a participant is walking (meters/second) Will be compared across timepoints.

Outcome measures

Outcome measures
Measure
Individuals With Stroke
n=18 Participants
Individuals with stroke who meet inclusion and exclusion criteria were included in Aim 1 and Aim 2 of the study. In aim 1, they engaged in a standard neurological screen and participated in clinic- and home-based walking trials. In Aim 2, they underwent a single session of step length symmetry training and submitted a series of home walking videos to track how durable improvements were from the clinic to home.
Neurologically Intact Adults
n=25 Participants
Healthy Adults/Adults without Stroke participated in Aim 1, but not Aim 2 of the study. They underwent the same screening and neurological assessment as participants with stroke and performed clinic-based and home-based walking trials. They did not receive intervention.
Self Selected Gait Speed
Clinic Data - Baseline
0.70 m/s
Standard Deviation 0.38
1.01 m/s
Standard Deviation 0.28
Self Selected Gait Speed
Home Data - Baseline
0.73 m/s
Standard Deviation 0.47
1.07 m/s
Standard Deviation 0.64

PRIMARY outcome

Timeframe: Aim 2: clinic before training, clinic after training, same day transfer, 1-day transfer, 3-day transfer, 1-week transfer

Population: 8 participants had full data sets and videos at all time points related to Aim 2 of this study. Only complete data sets have been analyzed at this time.

The normalized difference between short step length and long step length; a spatial parameter absolute value of (left step length - right step length) / left step length + right step length

Outcome measures

Outcome measures
Measure
Individuals With Stroke
n=8 Participants
Individuals with stroke who meet inclusion and exclusion criteria were included in Aim 1 and Aim 2 of the study. In aim 1, they engaged in a standard neurological screen and participated in clinic- and home-based walking trials. In Aim 2, they underwent a single session of step length symmetry training and submitted a series of home walking videos to track how durable improvements were from the clinic to home.
Neurologically Intact Adults
Healthy Adults/Adults without Stroke participated in Aim 1, but not Aim 2 of the study. They underwent the same screening and neurological assessment as participants with stroke and performed clinic-based and home-based walking trials. They did not receive intervention.
Step Length Asymmetry (Transfer)
Clinic Pretest (before training)
0.14 unitless
Standard Deviation 0.11
Step Length Asymmetry (Transfer)
Clinic Posttest (immedaitely after training)
0.21 unitless
Standard Deviation 0.15
Step Length Asymmetry (Transfer)
Home - training day follow-up
0.20 unitless
Standard Deviation 0.19
Step Length Asymmetry (Transfer)
Home - 1-day after training
0.16 unitless
Standard Deviation 0.16
Step Length Asymmetry (Transfer)
Home - 3-days after training
0.29 unitless
Standard Deviation 0.46
Step Length Asymmetry (Transfer)
Home - 7 days after training
0.25 unitless
Standard Deviation 0.34

OTHER_PRE_SPECIFIED outcome

Timeframe: Measured once, during the first session which takes place on a single day.

Population: Data from three individuals with stroke and three individuals without stroke were excluded from analysis due to insufficient data quality. Issues included pixelated or blurry videos, failure to keep the recording device stationary, or inaccurate identification of key landmarks during pose estimation. Ultimately, the data from 43 participants were included in data analysis.

Depression will be assessed with the Patient Health Questionnaire (PHQ-9). This is a multipurpose self-report instrument for screening, diagnosing, monitoring and measuring the severity of depression. Each of 9 items are scored from 0 (not at all) - 3 (nearly every day). Total scores are reported. Total scores range from 0-27. Higher scores represent more severe depression. Total scores of 5, 10, 15, and 20 represent cut points for mild, moderate, moderately severe and severe depression, respectively.

Outcome measures

Outcome measures
Measure
Individuals With Stroke
n=18 Participants
Individuals with stroke who meet inclusion and exclusion criteria were included in Aim 1 and Aim 2 of the study. In aim 1, they engaged in a standard neurological screen and participated in clinic- and home-based walking trials. In Aim 2, they underwent a single session of step length symmetry training and submitted a series of home walking videos to track how durable improvements were from the clinic to home.
Neurologically Intact Adults
n=25 Participants
Healthy Adults/Adults without Stroke participated in Aim 1, but not Aim 2 of the study. They underwent the same screening and neurological assessment as participants with stroke and performed clinic-based and home-based walking trials. They did not receive intervention.
Depression Via PHQ-9
5.11 scores on a scale
Standard Deviation 4.65
4.08 scores on a scale
Standard Deviation 4.70

OTHER_PRE_SPECIFIED outcome

Timeframe: Measured once, during the first session which takes place on a single day.

Population: Data from three individuals with stroke and three individuals without stroke were excluded from analysis due to insufficient data quality. Issues included pixelated or blurry videos, failure to keep the recording device stationary, or inaccurate identification of key landmarks during pose estimation. Ultimately, the data from 43 participants were included in data analysis.

The Berg Balance Scale is a 14-item objective measure that assesses static balance and fall risk in adults. Scores range from 0-56 with higher scores representing better balance (better outcomes). Total scores are reported. Scores from 0 to 20 represent a high fall risk; scores 21 to 40 represent a medium fall risk; scores 41-56 represent a low fall risk.

Outcome measures

Outcome measures
Measure
Individuals With Stroke
n=18 Participants
Individuals with stroke who meet inclusion and exclusion criteria were included in Aim 1 and Aim 2 of the study. In aim 1, they engaged in a standard neurological screen and participated in clinic- and home-based walking trials. In Aim 2, they underwent a single session of step length symmetry training and submitted a series of home walking videos to track how durable improvements were from the clinic to home.
Neurologically Intact Adults
n=25 Participants
Healthy Adults/Adults without Stroke participated in Aim 1, but not Aim 2 of the study. They underwent the same screening and neurological assessment as participants with stroke and performed clinic-based and home-based walking trials. They did not receive intervention.
Berg Balance Scale
42.00 scores on a scale
Standard Deviation 11.92
52.52 scores on a scale
Standard Deviation 5.04

Adverse Events

Individuals With Stroke

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Neurologically Intact Adults

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Kendra Cherry-Allen, PhD, PT, DPT

Western University of Health Sciences

Phone: 541.259.0473

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place